An international view of hydroxyethyl starches

Intensive Care Medicine

Volumn 25, Issue 3, 1999, Pages 258-268

  Treib, J ^a   Baron, J F ^b   Grauer, M T ^a   Strauss, R G ^c  

^a SAARLAND UNIVERSITY   (Germany)

^b HÔPITAL BROUSSAIS   (France)

^c UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; CARBON; HETASTARCH; PLASMA SUBSTITUTE; VON WILLEBRAND FACTOR;

ANAPHYLAXIS; BLEEDING; BLOOD CLOTTING; BLOOD CLOTTING DISORDER; BLOOD RHEOLOGY; CHEMICAL REACTION; DEGRADATION; DRUG ACCUMULATION; EUROPE; FIBRIN CLOT; HUMAN; KIDNEY TRANSPLANTATION; MARKETING; METABOLISM; MOLECULAR SIZE; MOLECULAR WEIGHT; PRURITUS; REVIEW; THROMBOCYTE FUNCTION; UNITED STATES; URINARY EXCRETION;

BLOOD COAGULATION; EUROPE; HEMORHEOLOGY; HETASTARCH; HUMANS; MOLECULAR WEIGHT; PLASMA SUBSTITUTES; UNITED STATES;

EID: 0033025682     PISSN: 03424642     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001340050833     Document Type: Review

References (82)

1. 1. Warren BB, Durieux ME (1997) Hydroxyethyl starch: safe or not? Anesth Analg 84: 206-212
2. 2. Treib J, Haass A, Schimrigk K (1997) European hydroxyethyl starch: a safe and inexpensive alternative to albumine. Anesth Analg 85: 709
3. 3. Thompson WL (1980) Hydroxyethyl starch. Dev Biol Stand 48: 259-266
4. 4. Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT, Jung F, Wenzel E, Schimrigk K (1995) HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 74: 1452-1456
5. 5. Rackow EC, Falk JL, Fein IA, Siegel JS, Packman MI, Haupt MT, Kaufman BS, Putnam D (1983) Fluid resuscitation in circulatory shock: a comparison of the cardiorespiratory effects of albumin, hetastarch, and saline solutions in patients with hypovolemic and septic shock. Crit Care Med 11: 839-850
6. 6. Kirklin JK, Lell WA, Kouchoukos NT (1984) Hydroxyethyl starch versus albumin for colloid infusion following cardiopulmonary bypass in patients undergoing myocardial revascularization. Ann Thorac Surg 37: 40-46
7. 7. Moggio RA, Rha CC, Somberg ED, Praeger PI, Pooley RW, Reed GE (1983) Hemodynamic comparison of albumin and hydroxyethyl starch in postoperative cardiac surgery patients. Crit Care Med 12: 943-945
8. 8. Diehl JT, Lester JLD, Cosgrove DM (1982) Clinical comparison of hetastarch and albumin in postoperative cardiac patients. Ann Thorac Surg 34: 674-679
9. 9. London MJ, Ho JS, Triedman JK, Verrier ED, Levin J, Merrick SH, Hanley FL, Browner WS, Mangano DT (1989) A randomized clinical trial of 10% pentastarch (low molecular weight hydroxyethyl starch) versus 5% albumin for plasma volume expansion after cardiac operations. J Thorac Cardiovasc Surg 97: 785-797
10. 10. Korttila K, Grohn P, Gordin A, Sundberg S, Salo H, Nissinen E, Mattila MA (1984) Effect of hydroxyethyl starch and dextran on plasma volume and blood hemostasis and coagulation. J Clin Pharmacol 24: 273-282
11. 11. Mishler JM, Ricketts CR, Parkhouse EJ (1980) Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study. J Clin Pathol 33: 155-159
12. 12. Ferber HP, Nitsch E, Forster H (1985) Studies on hydroxyethyl starch. Part II: changes of the molecular weight distribution for hydroxyethyl starch types 450/0.7, 450/0.5, 450/0.3, 300/0.4, 200/ 0.7, 200/0.5, 200/0.3 and 200/0.1 after infusion in serum and urine of volunteers. Arzneimittelforschung 35: 615-622
13. 13. Degrémont AC, Ismail M, Arthaud M, Oulare B, Mundler O, Paris M, Baron JF (1995) Mechanisms of postoperative prolonged plasma volume expansion with low molecular weight hydroxyethyl starch (HES 200/0.62, 6%). Intensive Care Med 21: 577-583
14. 14. Metcalf W, Papadopoulos A, Tufaro R, Barth A (1970) A clinical physiologic study of hydroxyethyl starch. Surg Gynecol Obstet 131:255-267
15. 15. Kohler H, Zschiedrich H, Clasen R, Linfante A, Gamm H (1982) The effects of 500 ml 10% hydroxyethyl starch 200/0.5 and 10% dextran 40 on blood volume, colloid osmotic pressure and renal function in human volunteers. Anaesthesist 31: 61-67
16. 16. Mishler JM, Parry ES, Sutherland BA, Bushrod JR (1979) A clinical study of low molecular weight-hydroxyethyl starch, a new plasma expander. Br J Clin Pharmacol 7: 619-622
17. 17. Kilian J, Spilker D, Borst R (1975) The effect of 6% hydroxyethyl starch, 45% dextran 60 and 5.5% oxy-poly-gelatine on blood volume and circulation in human volunteers. Anaesthesist 24: 193-197
18. 18. Kohler H, Kirch W, Klein H, Distler A (1978) The effect of 6% hydroxyethyl starch 450/0.7, 10% dextran 40 and 3.5% gelatin on plasma volume in patients with terminal renal failure. Anaesthesist 27: 421-426
19. 19. Hempel V, Metzger G, Unseld H, Schorer R (1975) The influence of hydroxyethyl starch solutions on circulation and on kidney function in hypovolaemie patients. Anaesthesist 24: 198-201
20. 20. Lazrove S, Waxman K, Shippy C, Shoemaker WC (1980) Hemodynamic, blood volume, and oxygen transport responses to albumin and hydroxyethyl starch infusions in critically ill postoperative patients. Crit Care Med 8: 302-306
21. 21. Sade RM, Stroud MR, Crawford FA Jr, Kratz JM, Dearing JP, Bartles DM (1983) A prospective randomized study of hydroxyethyl starch, albumin, and lactated Ringer's solution as priming fluid for cardiopulmonary bypass. J Thorac Cardiovasc Surg 89: 713-722
22. 22. Saunders CR, Carlisle L, Rick RL (1983) Hydroxyethyl starch versus albumin in cardiopulmonary bypass prime solutions. Ann Thorac Surg 36: 532-539
23. 23. Lumb PD (1987) A comparison between 25% albumin and 6% hydroxyethyl starch solutions on lung water accumulation during and immediately after cardiopulmonary bypass. Ann Surg 206: 210-213
24. 24. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH (1989) Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 17: 394-398
25. 25. Baron JF, De Kegel D, Prost AC, Mundler O, Arthaud M, Basset G, Maistre G, Masson F, Carayon A, Landault C et al (1991) Low molecular weight hydroxyethyl starch 6% compared to albumin 4% during intentional hemodilution. Intensive Care Med 17: 141-148
26. 26. Messmer K, Brendel W, Sunder-Plassmann L, Holper K (1969) The use of colloidal solutions for extreme hemodilution. Bibl Haematol 33: 261-269
27. 27. Laxenaire MC, Charpentier C, Feldman L (1994) Anaphylactoid reactions to colloid plasma substitutes: incidence, risk factors, mechanisms. A French multicenter prospective study. Ann Fr Anesth Reanim 13: 301-310
28. 28. Haupt MT, Rackow EC (1982) Colloid osmotic pressure and fluid resuscitation with hetastarch, albumin, and saline solutions. Crit Care Med 10: 159-162
29. 29. Hankeln K, Radel C, Beez M, Laniewski P, Bohmert F (1989) Comparison of hydroxyethyl starch and lactated Ringer's solution on hemodynamics and oxygen transport of critically ill patients in prospective crossover studies. Crit Care Med 17: 133-135
30. 30. Palanzo DA, Parr GV, Bull AP, Williams DR, O'Neill MJ, Waldhausen JA (1982) Hetastarch as a prime for cardiopulmonary bypass. Ann Thorac Surg 34: 680-683
31. 31. Mishler JM, Ricketts CR, Parkhouse EJ (1980) Post-transfusion survival of hydroxyethyl starch 450/0.70 in man: a long-term study. J Clin Pathol 33: 155-159
32. 32. Rackow EC, Mecher C, Astiz ME, Griffel M, Falk JL, Weil MH (1989) Effects of pentastarch and albumin infusion on cardiorespiratory function and coagulation in patients with severe sepsis and systemic hypoperfusion. Crit Care Med 17: 394-398
33. 33. Messmer K, Jesch F (1978) Volumenersatz and Haemodilution durch Hydroxyaethylstaerke. Infusionstherapie 5: 169-177
34. 34. Treib J, Haass A, Pindur G, Seyfert UT, Treib W, Grauer MT, Jung F, Wenzel E, Schimrigk K (1995) HES 200/0.5 is not HES 200/0.5. Influence of the C2/C6 hydroxyethylation ratio of hydroxyethyl starch (HES) on hemorheology, coagulation and elimination kinetics. Thromb Haemost 74: 1452-1456
35. 35. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K (1996) All medium starches are not the same. Influence of degree of substitution of hydroxyethyl starch on plasma volume, hemorheologic conditions, and coagulation. Transfusion 36: 450-455
36. 36. Treib J, Haass A, Pindur G, Grauer MT, Seyfert UT, Treib W, Wenzel E, Schimrigk K (1996) Influence of low molecular weight hydroxyethyl starch on hemostasis and hemorheology. Haemostasis 26: 258-265
37. 37. Treib J, Haass A, Pindur G, Grauer MT, Treib W, Wenzel E, Schimrigk K (1997) Increased hemorrhagic risk after repeated infusion of highly substituted medium molecular weight hydroxyethyl starch. Arzneim Forsch/Drug Res 47: 18-22
38. 38. Kiesewetter H, Waldhausen P, Schimetta W, Wilhelm H-J, Koscielny J (1992) Possible side effects of a HES infusion and their treatment. In: Koscielny J, Kiesewetter H, Jung F, Haass A (eds) Hemodilution. New aspects in the management of circulatory blood flow. Improvement of macro-and microcirculation. Springer, Berlin Heidelberg New York, pp 165-170
39. 39. Szepfalusi Z, Parth E, Jurecka W, Luger TA, Kraft D (1993) Human monocytes and keratinocytes in culture ingest hydroxyethylstarch. Arch Dermatol Res 285: 144-150
40. 40. Thompson WL, Fukushima T, Rutherford RB, Walton RP (1979) Intravasale Persistenz, Gewebsspeicherung and Ausscheidung von Hydroxyaethylstaerke (HAES). Infusionstherapie 6: 151-155
41. 41. Legendre C, Thervet E, Page B, Percheron A, Noel LH, Kreis H (1993) Hydroxyethylstarch and osmotic-nephrosis-like lesions in kidney transplantation. Lancet 342: 248-249
42. 42. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P (1996) Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet 348: 1620-1622
43. 43. Coronel B, Mercatello A, Martin X, Lefrancois N (1997) Hydroxyethylstarch and renal function in kidney transplant recipients. Lancet 349: 9055
44. 44. Symington BE (1986) Hetastarch and bleeding complications. Ann Intern Med 105: 627-628
45. 45. Bianchine JR (1987) Letter. N Engl J Med 317: 965
46. 46. Cully MD, Larson CP, Silverberg GD (1987) Hetastarch coagulopathy in a neurosurgical patient. Anesthesiology 66: 707-708
47. 47. Damon L, Adams M, Stricker RB, Ries C (1987) Intracranial bleeding during treatment with hydroxyethyl starch. N Engl J Med 317: 964-965
48. 48. Sanfelippo MJ, Suberviola PD, Geimer NF (1987) Development of a von Willebrand like syndrome after prolonged use of hydroxyethyl starch. Am J Clin Pathol 88: 653-655
49. 49. Abramson N (1988) Plasma expanders and bleeding. Ann Intern Med 108: 307
50. 50. Lockwood DNJ, Bullen C, Machin SJ (1988) A severe coagulophathy following volume replacement with hydroxyethylstarch in a jehovah's witness. Anaesthesia 43: 391-393
51. 51. Chang JC, Gross HM, Jang NS (1990) Disseminated intravascular coagulation due to intravenous administration of hetastarch. Am J Med Sci 300: 301-303
52. 52. Lazarchick J, Conroy JM (1995) The effect of 6% hydroxyethyl starch and desmopressin infusion on vWF: ristocetin cofactor activity. Ann Clin Lab Sci 25: 306-309
53. 53. Trumble ER, Muizelaar JP, Myseros JS, Choi SC, Warren BB (1995) Coagulopathy with the use of hetastarch in the treatment of vasospasm. J Neurosurg 82: 44-47
54. 54. Strauss RG, Stansfield C, Henriksen A, Villhauer PJ (1988) Pentastarch may cause fewer effects on coagulation than hetastarch. Transfusion 28: 257-260
55. 55. Macintyre E, Mackie IJ, Ho D, Tinker J, Bullen C, Machin SJ (1985) The haemostatic effects of hydroxyethyl starch (HES) used as a volume expander. Intensive Care Med 11: 300-303
56. 56. Stump DC, Strauss RG, Henriksen RA, Petersen RE, Saunders R (1985) Effects of hydroxyethyl starch on blood coagulation, particularly F VIII. Transfusion 25: 349-354
57. 57. Dalrymple HM, Aitchison R, Collins P, Sekhar M, Colvin B (1992) Hydroxyethyl starch induced acquired von Willebrand's disease. Clin Lab Haematol 14: 209-211
58. 58. Penner M, Fingerhut D, Tacke A (1990) Effect of a new 10% hydroxyethyl starch solution HES/270/0.5 on blood coagulation, blood loss and hemodynamics in comparison with 3.5% PPL. Infusionstherapie 17: 314-318
59. 59. van den Brink WA, van Genderen P, Thijsse WJ, Michiels JJ (19%) Hetastarch coagulopathy. J Neurosurg 85: 367
60. 60. Treib J, Haass A, Pindur G, Miyachita C, Grauer MT, Jung F, Wenzel E, Schimrigk K (1996) Highly substituted hydroxyethyl starch (HES 200/0.62) leads to a type 1 von Willebrand syndrome after repeated administration. Haemostasis 26: 210-213
61. 61. Conroy JM, Fishman RL, Reeves ST, Pinosky ML, Lazarchick J (1996) The effects of desmopressin and 6% hydroxyethyl starch on F VIII:C. Anesth Analg 83: 804-807
62. 62. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K (1997) Avoiding an impairment of F VIII:C by using hydroxyethyl starch with a low in vivo molecular weight. Anesth Analg 84: 1391
63. 63. Batlle J, Del Rio F, Fernandez MF, Martin R, Borrasca A (1985) Effect of dextran on F VIII/vWF structure and function. Thromb Haemost 54: 697-699
64. 64. Arkel YS, Lynch J, Kamiyama M (1994) Treatment of acquired von Willebrand syndrome with intravenous immunoglobulin. Thromb Haemostas 72 643-651
65. 65. Siostrzonek P, Niessner H, Deutsch E, Lechner K, Korninger C, Pabinger I, Heinz R (1985) Vier Faelle mit erworbenem von Willebrand-Syndrom and monoklonaler Gammopathie. Langzeitverlauf sowie diagnostische and therapeutische Problematik. In: Landbeck G (ed) 16. Haemophilie symposion, Hamburg. Springer, Berlin Heidelberg New York, pp 248-256
66. 66. Treib J, Haass A, Pindur G, Treib W, Wenzel E., Schimrigk K (1996) Influence on intravascular molecular weight of hydroxyethyl starch on platelets during a long-term hemodilution. Eur J Hematol 56: 168-172
67. 67. Treib J, Haass A, Pindur G, Treib W, Wenzel E, Schimrigk K (1996) Influence of low and medium molecular weight hydroxyethyl starch on platelets during a long-term hemodilution. Arzneim Forsch/Drug Res 46: 1064-1066
68. 68. Treib J, Haass A, Pindur G, Grauer MT, Wenzel E, Schimrigk K (1996) Abnahme des Thrombozytenvolumens durch mehrtägige Infusion von hochsubstituierter mittelmolekularer Hydroxyäthylstärke (HÄS 200/0,62). Wien Klin Wochenschr 108: 20-23
69. 69. Kristensen SD, Milner PC, Martin JF (1988) Bleeding time and platelet volume in acute myocardial infarction. A 2 year follow-up study. Thromb Haemost 59: 353-356
70. 70. Threatte GA (1993) Usefulness of the mean platelet volume. Clin Lab Med 13: 937-950
71. 71. Karpatkin S (1978) Heterogeneity of human platelets, correlation of platelet function with platelet volume. Blood 51: 307-316
72. 72. Eldor A, Avitzour M, Or R, Hanna R, Penchas S (1982) Prediction of haemorrhagic diathesis in thrombocytopenia by mean platelet volume. BMJ 285: 397-400
73. 73. Thompson CB, Eaton KA, Princiotta SM, Rushin CA, Valeri CR (1982) Size dependent platelet subpopulations: relationship of platelet volume to ultrastructure, enzymatic activity and function. Br J Haematol 50: 509-519
74. 74. Boldt J, Zickmann B, Rapin J, Hammermann H, Dapper F, Hempelmann G (1994) Influence of volume replacement with different HES-solutions on microcirculatory blood flow in cardiac surgery. Acta Anaesthesiol Scand 38: 432-438
75. 75. Chien S, Jan KM (1973) Ultrastructural basis of the mechanism of rouleaux formation. Microvasc Res 5: 155-166
76. 76. Haass A, Stoll M, Treib J (1992) Hemodilution in cerebral circulatory disturbances: indications, implementation, additional drug treatment and alternatives. In: Koscielny J, Kiesewetter H, Jung F, Haass A (eds) Hemodilution. New aspects in the management of circulatory blood flow. Improvement of macro-and microcirculation. Springer, Berlin Heidelberg New York, pp 53-114
77. 77. Haass A, Treib J, Stoll M (1992) Hemorheological parameters of hydroxyethyl starch 200/0.62 as a basis for hemodilution. Clin Hemorheol 12: 17-26
78. 78. Haass A, Kroemer H, Jaeger H, Mueller K, Decker I, Wagner EM, Schimrigk K (1986) Dextran 40 oder HES 200/0.5? Haemorheologic der Langzeitbehandlung beim ischaemischen zerebralen Insult. Dtsch Med Wochenschr 111: 1681-1686
79. 79. Haass A, Kroemer H, Jaeger H, Oest A, Schimrigk K (1987) Similar and opposite hemorheological effects of dextran 40 and hydroxyethyl starch in hemodilution therapy for stroke. In: Hartmann A, Kuschinsky W (eds) Cerebral ischemia and hemorheology. Springer Berlin Heidelberg New York, pp 488-495
80. 80. Strauss RG (1988) Volume replacement and coagulation: a comparative review. J Cardiothorac Vase Anesth 2: 24-32
81. 81. Treib J, Haass A, Pindur G (1997) Coagulation disorders caused by hydroxyethyl starch. Thromb Haemost 78: 974-983
82. 82. Grauer MT, Treib J (1998) The effect of HES on coagulation is difficult to assess in vitro. Br J Anaesth 80: 125-126